Lysine Restriction and Pyridoxal Phosphate Administration in a NADK2 Patient
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(ALDH1A3) for the Maintenance of Non-Small Cell Lung Cancer Stem Cells Is Associated with the STAT3 Pathway
Author Manuscript Published OnlineFirst on June 6, 2014; DOI: 10.1158/1078-0432.CCR-13-3292 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Essential role of aldehyde dehydrogenase 1A3 (ALDH1A3) for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway Chunli Shao1,2, James P. Sullivan3, Luc Girard1,2, Alexander Augustyn1,2, Paul Yenerall1,2, Jaime Rodriguez4, Hui Liu4, Carmen Behrens4, Jerry W. Shay5, Ignacio I. Wistuba4, John D. Minna 1,2,6,7 1Hamon Center for Therapeutic Oncology Research, 2Simmons Comprehensive Cancer Center, 3Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, 02114, 4Department of Translational Molecular Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77054, 5Department of Cell Biology, 6Department of Pharmacology, 7Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, 75390, USA. Running Title: ALDH1A3 in non-small cell lung cancer stem cells Keywords: Lung cancer, cancer stem cells, ALDH1A3, STAT3, Stattic Financial Support This project was supported by CPRIT, NCI SPORE P50CA70907, UTSW Cancer Center Support Grant 5P30-CA142543, and the Gillson-Longenbaugh Foundation. Address Correspondence: John D. Minna, M.D. 6000 Harry Hines Blvd Dallas, TX 75390-8593 Hamon Center for Therapeutic Oncology Research UT Southwestern Medical Center Phone: 214-648-4900; Fax: 214-648-4940 [email protected] Disclosure of Potential Conflict of Interest The authors indicate no potential conflicts of interest. Word count: 4583 Total number of figures and tables: 6 figures Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2014 American Association for Cancer Research. -
Pyridoxal Phosphate Is Better Than Pyridoxine for Controlling Idiopathic Intractable Epilepsy
512 ORIGINAL ARTICLE Arch Dis Child: first published as 10.1136/adc.2003.045963 on 25 April 2005. Downloaded from Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy H-S Wang, M-F Kuo, M-L Chou, P-C Hung, K-L Lin, M-Y Hsieh, M-Y Chang ............................................................................................................................... Arch Dis Child 2005;90:512–515. doi: 10.1136/adc.2003.045963 Aim: To study the difference between pyridoxine (PN) and its active form, pyridoxal phosphate, (PLP) in control of idiopathic intractable epilepsy in children. Methods: Among 574 children with active epilepsy, 94 (aged 8 months to 15 years) were diagnosed with idiopathic intractable epilepsy for more than six months. All received intravenous PLP 10 mg/kg, then 10 mg/kg/day in four divided doses. If seizures recurred within 24 hours, another dose of 40 mg/kg was See end of article for given, followed by 50 mg/kg/day in four divided doses. For those patients whose seizures were totally authors’ affiliations controlled, PLP was replaced by the same dose of oral PN. If the seizure recurred, intravenous PLP was ....................... infused followed by oral PLP 50 mg/kg/day. Correspondence to: Results: Fifty seven patients had generalised seizures (of whom 13 had infantile spasms) and 37 had focal Dr M-F Kuo, Division of seizure. Eleven had dramatic and sustained responses to PLP; of these, five also responded to PN. Within (Pediatric) Neurosurgery, six months of treatment with PLP or PN, five of the 11 patients were seizure free and had their previous Department of Surgery, National Taiwan University antiepileptic medicine tapered off gradually. -
Overall Survival of Pancreatic Ductal Adenocarcinoma Is Doubled by Aldh7a1 Deletion in the KPC Mouse
Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse Jae-Seon Lee1,2*, Ho Lee3*, Sang Myung Woo4, Hyonchol Jang1, Yoon Jeon1, Hee Yeon Kim1, Jaewhan Song2, Woo Jin Lee4, Eun Kyung Hong5, Sang-Jae Park4, Sung- Sik Han4§§ and Soo-Youl Kim1§ 1Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Republic of Korea. 2Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea. 3Graduate School of Cancer Science and Policy, 4Department of Surgery, Center for Liver and Pancreatobiliary Cancer and 5Department of Pathology, National Cancer Center, Goyang, Republic of Korea. Correspondence §Corresponding author: [email protected] (S.-Y.K.) §§Co-corresponding author: [email protected] (S.-S.H.) *These authors contributed equally to this work 1 Abstract Rationale: The activity of aldehyde dehydrogenase 7A1 (ALDH7A1), an enzyme that catalyzes the lipid peroxidation of fatty aldehydes was found to be upregulated in pancreatic ductal adenocarcinoma (PDAC). ALDH7A1 knockdown significantly reduced tumor formation in PDAC. We raised a question how ALDH7A1 contributes to cancer progression. Methods: To answer the question, the role of ALDH7A1 in energy metabolism was investigated by knocking down and knockdown gene in mouse model, because the role of ALDH7A1 has been reported as a catabolic enzyme catalyzing fatty aldehyde from lipid peroxidation to fatty acid. Oxygen consumption rate (OCR), ATP production, mitochondrial membrane potential, proliferation assay and immunoblotting were performed. In in vivo study, two human PDAC cell lines were used for pre-clinical xenograft model as well as spontaneous PDAC model of KPC mice was also employed for anti-cancer therapeutic effect. -
Composition: Each
______________________________________________________________________________________________________________ Composition: Each Tablet Contains L-Methylfolate 1mg Mecobalamin 1500 mcg Pyridoxal 5’-phosphate 0.5mg Pharmacokinetic properties: L-methylfolate is a water soluble molecule which is primarily excreted via the kidneys. In a study of subjects with coronary artery disease (n=21), peak plasma levels were reached in 1-3 hours following ORAL/PARENTERAL administration. Peak concentrations of L-methylfolate were found to be more than seven times higher than folic acid (129 ng ml-1 vs. 14.1 ng ml-1) following ORAL/PARENTERAL administration. The mean elimination half-life is approximately 3 hours after 5mg of oral L- methylfolate, administered daily for 7 days. The mean values for Cmax, Tmax, and AUC0-12 were 129 ng ml-1, 1.3 hr., and 383 respectively. Red blood cells (RBCs) appear to be the storage depot for folate, as RBC levels remain elevated for periods in excess of 40 days following discontinuation of supplementation. Plasma protein binding studies showed that L-methylfolate is 56% bound to plasma proteins. Mecobalamin substances bind to intrinsic factor; a glycoprotein secreted by the gastric mucosa, and are then actively absorbed from the gastrointestinal tract. Absorption is impaired in patients with an absence of intrinsic factor, with a malabsorption syndrome or with disease or abnormality of the gut, or after gastrectomy. Absorption from the gastrointestinal tract can also occur by passive diffusion; little of the vitamin present in food is absorbed in this manner although the process becomes increasingly important with larger amounts such as those used therapeutically. After intranasal dosage, peak plasma concentrations of cyanocobalamin have been reached in 1 to 2 hours. -
Insights Into Aldehyde Dehydrogenase Enzymes: a Structural Perspective
REVIEW published: 14 May 2021 doi: 10.3389/fmolb.2021.659550 Insights into Aldehyde Dehydrogenase Enzymes: A Structural Perspective Kim Shortall, Ahmed Djeghader, Edmond Magner and Tewfik Soulimane* Department of Chemical Sciences, Bernal Institute, University of Limerick, Limerick, Ireland Aldehyde dehydrogenases engage in many cellular functions, however their dysfunction resulting in accumulation of their substrates can be cytotoxic. ALDHs are responsible for the NAD(P)-dependent oxidation of aldehydes to carboxylic acids, participating in detoxification, biosynthesis, antioxidant and regulatory functions. Severe diseases, including alcohol intolerance, cancer, cardiovascular and neurological diseases, were linked to dysfunctional ALDH enzymes, relating back to key enzyme structure. An in-depth understanding of the ALDH structure-function relationship and mechanism of action is key to the understanding of associated diseases. Principal structural features 1) cofactor binding domain, 2) active site and 3) oligomerization mechanism proved critical in maintaining ALDH normal activity. Emerging research based on the combination of structural, functional and biophysical studies of bacterial and eukaryotic ALDHs contributed to the appreciation of diversity within the superfamily. Herewith, we Edited by: discuss these studies and provide our interpretation for a global understanding of Ashley M Buckle, ALDH structure and its purpose–including correct function and role in disease. Our Monash University, Australia analysis provides a synopsis -
Vitamin B6 Metabolism and Regulation of Pyridoxal Kinase
Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2009 VITAMIN B6 METABOLISM AND REGULATION OF PYRIDOXAL KINASE Amit Gandhi Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Chemicals and Drugs Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2008 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Amit K. Gandhi 2009 All Rights Reserved VITAMIN B 6 METABOLISM AND REGULATION OF PYRIDOXAL KINASE A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. By AMIT K. GANDHI M.S (Pharmaceutical Science), Rajiv Gandhi University, Indore, India, 2003 B.Pharm, Rajiv Gandhi University, Indore, India, 2001 Director: Martin K. Safo, Ph.D Assistant Professor, Department of Medicinal Chemistry Virginia Commonwealth University Richmond, Virginia December, 2009 Acknowledgement I would like to take this opportunity to express my deep gratitude and profound respect to my advisor, Dr. Martin K. Safo, for his supervision, advice, and guidance in this research work. His support and insight have been invaluable in the progression of my research. I also appreciate his words of encouragement, which kept me always in an innovative mood and guided me at all the times to bring about the best in me. He is my mentor and teacher whom I shall remember forever. -
A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer
cancers Article A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer Nkechiyere G. Nwani 1, Salvatore Condello 2 , Yinu Wang 1, Wendy M. Swetzig 1, Emma Barber 1, Thomas Hurley 3,4 and Daniela Matei 1,5,6,* 1 Department of Obstetrics and Gynecology, Northwestern University, Chicago, IL 60611, USA; [email protected] (N.G.N.); [email protected] (Y.W.); [email protected] (W.M.S.); [email protected] (E.B.) 2 Department of Obstetrics and Gynecology, Indiana University, Indianapolis, IN 46202, USA; [email protected] 3 Department of Biochemistry and molecular Biology, Indiana University, Indianapolis, IN 46202, USA; [email protected] 4 Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA 5 Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA 6 Jesse Brown VA Medical Center, Chicago, IL 60612, USA * Correspondence: [email protected] Received: 8 February 2019; Accepted: 3 April 2019; Published: 8 April 2019 Abstract: A small of population of slow cycling and chemo-resistant cells referred to as cancer stem cells (CSC) have been implicated in cancer recurrence. There is emerging interest in developing targeted therapeutics to eradicate CSCs. Aldehyde-dehydrogenase (ALDH) activity was shown to be a functional marker of CSCs in ovarian cancer (OC). ALDH activity is increased in cells grown as spheres versus monolayer cultures under differentiating conditions and in OC cells after treatment with platinum. Here, we describe the activity of CM37, a newly identified small molecule with inhibitory activity against ALDH1A1, in OC models enriched in CSCs. Treatment with CM37 reduced OC cells’ proliferation as spheroids under low attachment growth conditions and the expression of stemness-associated markers (OCT4 and SOX2) in ALDH+ cells fluorescence-activated cell sorting (FACS)-sorted from cell lines and malignant OC ascites. -
Phosphate-Dependent Enzymes Involved in Biotin Biosynthesis: Structure, Reaction Mechanism and Inhibition☆
Biochimica et Biophysica Acta 1814 (2011) 1459–1466 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbapap Review Pyridoxal-5′-phosphate-dependent enzymes involved in biotin biosynthesis: Structure, reaction mechanism and inhibition☆ Stéphane Mann, Olivier Ploux ⁎ Laboratoire Charles Friedel, ENSCP Chimie ParisTech, UMR CNRS 7223, 11 rue Pierre et Marie Curie, F-75231 Paris Cedex 05, France article info abstract Article history: The four last steps of biotin biosynthesis, starting from pimeloyl-CoA, are conserved among all the Received 5 July 2010 biotin-producing microorganisms. Two enzymes of this pathway, the 8-amino-7-oxononanoate synthase Received in revised form 4 November 2010 (AONS) and the 7,8-diaminopelargonic acid aminotransferase (DAPA AT) are dependent on pyridoxal-5′- Accepted 10 December 2010 phosphate (PLP). This review summarizes our current understanding of the structure, reaction mechanism Available online 21 December 2010 and inhibition on these two interesting enzymes. Mechanistic studies as well as the determination of the crystal structure of AONS have revealed a complex mechanism involving an acylation with inversion of Keywords: fi fi 8-amino-7-oxononanoate synthase con guration and a decarboxylation with retention of con guration. This reaction mechanism is shared by the 7,8-diaminopelargonic acid aminotransferase homologous 5-aminolevulinate synthase and serine palmitoyltransferase. While the reaction catalyzed by Pyridoxal-5′-phosphate DAPA AT is a classical PLP-dependent transamination, the inactivation of this enzyme by amiclenomycin, a Enzyme reaction mechanism natural antibiotic that is active against Mycobacterium tuberculosis, involves the irreversible formation of an Inhibition adduct between PLP and amiclenomycin. -
Large-Scale Domain Motions and Pyridoxal-5'-Phosphate Assisted Radical Catalysis in Coenzyme † B12-Dependent Aminomutases
Int. J. Mol. Sci. 2014, 15, 3064-3087; doi:10.3390/ijms15023064 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Large-Scale Domain Motions and Pyridoxal-5'-Phosphate Assisted Radical Catalysis in Coenzyme † B12-Dependent Aminomutases Amarendra Nath Maity, Yung-Han Chen and Shyue-Chu Ke * Physics Department, National Dong Hwa University, Hualien 97401, Taiwan; E-Mails: [email protected] (A.N.M.); [email protected] (Y.-H.C.) † This paper is dedicated to Emeritus Professor Perry A. Frey (Biochemistry Department, University of Wisconsin at Madison, Madison, WI, USA) on the occasion of his 78th birthday. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +886-3863-3705; Fax: +886-3863-3690. Received: 27 November 2013; in revised form: 25 December 2013 / Accepted: 22 January 2014 / Published: 20 February 2014 Abstract: Lysine 5,6-aminomutase (5,6-LAM) and ornithine 4,5-aminomutase (4,5-OAM) are two of the rare enzymes that use assistance of two vitamins as cofactors. These enzymes employ radical generating capability of coenzyme B12 (5'-deoxyadenosylcobalamin, dAdoCbl) and ability of pyridoxal-5'-phosphate (PLP, vitamin B6) to stabilize high-energy intermediates for performing challenging 1,2-amino rearrangements between adjacent carbons. A large-scale domain movement is required for interconversion between the catalytically inactive open form and the catalytically active closed form. In spite of all the similarities, these enzymes differ in substrate specificities. 4,5-OAM is highly specific for D-ornithine as a substrate while 5,6-LAM can accept D-lysine and L-β-lysine. -
Prediagnostic Plasma Pyridoxal 5 -Phosphate (Vitamin B6) Levels
Published OnlineFirst August 9, 2012; DOI: 10.1158/1055-9965.EPI-12-0717-T Cancer Epidemiology, Research Article Biomarkers & Prevention Prediagnostic Plasma Pyridoxal 50-Phosphate (Vitamin B6) Levels and Invasive Breast Carcinoma Risk: The Multiethnic Cohort Galina Lurie1, Lynne R. Wilkens1, Yurii B. Shvetsov1, Nicholas J. Ollberding2, Adrian A. Franke1, Brian E. Henderson3, Laurence N. Kolonel1, and Marc T. Goodman1 Abstract Background: Evidence from experimental and epidemiologic studies suggests that vitamin B6 may reduce the risk of breast cancer. Methods: We examined the association of prediagnostic plasma concentrations of pyridoxal-50-phosphate (PLP), an active form of vitamin B6, with postmenopausal breast cancer risk in a case–control study nested in the multiethnic cohort in Hawaii and Southern California, including 706 cases and 706 controls matched on date of birth, ethnicity, study site, date of blood draw, time of blood draw, hours of fasting before blood draw, and use of menopausal hormones. OR and 95% confidence intervals (CI) were calculated using conditional logistic regression models. Results: Women with plasma PLP concentrations in the highest quartile had a 30% reduced risk of invasive breast cancer (CI: 0.50–0.98) as compared with the women in the lowest PLP quartile (P for trend ¼ 0.02). The association seemed to be limited in cases with hormone receptor-positive tumors (P for heterogeneity ¼ 0.04); and remained unchanged in the analysis restricted to women with blood samples collected more than one year before cancer diagnosis (OR ¼ 0.69; CI: 0.48–0.99; P for trend ¼ 0.03). Conclusions: These data suggest that higher circulating levels of vitamin B6 are associated with a reduced risk of invasive postmenopausal breast cancer. -
Summary Report
Pyridoxal 5-Phosphate: Summary Report Item Type Report Authors Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Yuen, Melissa V.; Mattingly, Ashlee N. Publication Date 2019-12 Keywords Pyridoxal; Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration; Pyridoxal Phosphate Rights Attribution-NoDerivatives 4.0 International Download date 02/10/2021 21:53:32 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12348 Summary Report Pyridoxal 5-Phosphate Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy December 2019 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATION ..................................................................................................... 4 METHODOLOGY ................................................................................................................... -
Aldehyde Dehydrogenase, Liver Disease and Cancer Wenjun Wang1, Chunguang Wang2, Hongxin Xu1, Yanhang Gao1
Int. J. Biol. Sci. 2020, Vol. 16 921 Ivyspring International Publisher International Journal of Biological Sciences 2020; 16(6): 921-934. doi: 10.7150/ijbs.42300 Review Aldehyde Dehydrogenase, Liver Disease and Cancer Wenjun Wang1, Chunguang Wang2, Hongxin Xu1, Yanhang Gao1 1. Department of Hepatology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin, 130021, China. 2. Department of Thoracic & Cardiovascular Surgery, Second Clinical College, Jilin University, Changchun, 130041, China. Corresponding author: Yanhang Gao, MD., PhD., Department of Hepatology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin, 130021, China. Email: [email protected]. Tel: +86 15804303019; +86 431 81875121; +86 431 81875106; Fax number: 0431-81875106. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.11.20; Accepted: 2020.01.03; Published: 2020.01.22 Abstract Acetaldehyde dehydrogenase 2 (ALDH2) is the key enzyme responsible for metabolism of the alcohol metabolite acetaldehyde in the liver. In addition to conversion of the acetaldehyde molecule, ALDH is also involved in other cellular functions. Recently, many studies have investigated the involvement of ALDH expression in viral hepatitis, alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), liver fibrosis, and liver cancer. Notably, ALDH2 expression has been linked with liver cancer risk, as well as pathogenesis and prognosis, and has emerged as a promising therapeutic target. Of note, approximately 8% of the world’s population, and approximately 30-40% of the population in East Asia carry an inactive ALDH2 gene.